(AVTR) Avantor - Overview
Stock: Materials, Consumables, Equipment, Services
| Risk 5d forecast | |
|---|---|
| Volatility | 58.5% |
| Relative Tail Risk | -14.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.95 |
| Alpha | -64.29 |
| Character TTM | |
|---|---|
| Beta | 1.161 |
| Beta Downside | 0.941 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.40% |
| CAGR/Max DD | -0.42 |
EPS (Earnings per Share)
Revenue
Description: AVTR Avantor January 06, 2026
Avantor, Inc. (NYSE:AVTR) supplies mission-critical products and services across biopharma, healthcare, education, government, advanced-technology, and applied-materials markets worldwide, operating in the Americas, Europe, Asia, the Middle East, and Africa.
The company’s catalog includes high-purity chemicals and reagents, lab consumables, formulated silicone materials, custom excipients, single-use assemblies, chromatography resins and columns, analytical sample-prep kits, microbiology products, clinical-trial kits, and fluid-handling tips.
In addition to consumables, Avantor offers equipment such as filtration and virus-inactivation systems, incubators, analytical instruments, ultra-low-temperature freezers, biosafety cabinets, peristaltic pumps, and related critical-environment supplies, plus on-site services ranging from lab and production support to procurement, scale-up, and biopharmaceutical development.
Key metrics (as of FY 2023) show revenue of roughly $13.5 billion, a 9 % YoY growth rate driven largely by expanding demand for single-use bioprocessing solutions and the resurgence of vaccine manufacturing, and an adjusted EBITDA margin near 15 %. The life-sciences tools sector benefits from a projected 8 % CAGR through 2028, underpinned by rising biologics pipelines, tighter regulatory scrutiny on contamination control, and sustained government spending on health-security infrastructure.
For a deeper, data-driven assessment of Avantor’s valuation dynamics, you might find ValueRay’s analytical platform worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -530.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.52 > 1.0 |
| NWC/Revenue: 16.37% < 20% (prev 2.05%; Δ 14.31% < -1%) |
| CFO/TA 0.05 > 3% & CFO 623.8m > Net Income -530.2m |
| Net Debt (3.58b) to EBITDA (138.7m): 25.82 < 3 |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (679.3m) vs 12m ago -0.50% < -2% |
| Gross Margin: 32.65% > 18% (prev 0.34%; Δ 3232 % > 0.5%) |
| Asset Turnover: 54.81% > 50% (prev 56.00%; Δ -1.19% > 0%) |
| Interest Coverage Ratio: -1.60 > 6 (EBITDA TTM 138.7m / Interest Expense TTM 169.8m) |
Altman Z'' 1.86
| A: 0.09 (Total Current Assets 2.45b - Total Current Liabilities 1.38b) / Total Assets 11.79b |
| B: 0.14 (Retained Earnings 1.67b / Total Assets 11.79b) |
| C: -0.02 (EBIT TTM -271.5m / Avg Total Assets 11.95b) |
| D: 0.91 (Book Value of Equity 5.64b / Total Liabilities 6.23b) |
| Altman-Z'' Score: 1.86 = BBB |
Beneish M -3.09
| DSRI: 1.08 (Receivables 1.07b/1.03b, Revenue 6.55b/6.78b) |
| GMI: 1.03 (GM 32.65% / 33.60%) |
| AQI: 0.95 (AQ_t 0.73 / AQ_t-1 0.76) |
| SGI: 0.97 (Revenue 6.55b / 6.78b) |
| TATA: -0.10 (NI -530.2m - CFO 623.8m) / TA 11.79b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of AVTR shares?
Over the past week, the price has changed by -1.85%, over one month by -23.80%, over three months by -17.83% and over the past year by -48.37%.
Is AVTR a buy, sell or hold?
- StrongBuy: 6
- Buy: 4
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AVTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.9 | 20.6% |
| Analysts Target Price | 10.9 | 20.6% |
AVTR Fundamental Data Overview February 21, 2026
P/S = 0.9587
P/B = 1.1361
Revenue TTM = 6.55b USD
EBIT TTM = -271.5m USD
EBITDA TTM = 138.7m USD
Long Term Debt = 3.92b USD (from longTermDebt, last quarter)
Short Term Debt = 30.8m USD (from shortTermDebt, last quarter)
Debt = 3.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.58b USD (from netDebt column, last quarter)
Enterprise Value = 9.86b USD (6.28b + Debt 3.95b - CCE 365.4m)
Interest Coverage Ratio = -1.60 (Ebit TTM -271.5m / Interest Expense TTM 169.8m)
EV/FCF = 19.92x (Enterprise Value 9.86b / FCF TTM 495.0m)
FCF Yield = 5.02% (FCF TTM 495.0m / Enterprise Value 9.86b)
FCF Margin = 7.55% (FCF TTM 495.0m / Revenue TTM 6.55b)
Net Margin = -8.09% (Net Income TTM -530.2m / Revenue TTM 6.55b)
Gross Margin = 32.65% ((Revenue TTM 6.55b - Cost of Revenue TTM 4.41b) / Revenue TTM)
Gross Margin QoQ = 31.49% (prev 32.42%)
Tobins Q-Ratio = 0.84 (Enterprise Value 9.86b / Total Assets 11.79b)
Interest Expense / Debt = 1.01% (Interest Expense 40.0m / Debt 3.95b)
Taxrate = 35.15% (28.4m / 80.8m)
NOPAT = -176.1m (EBIT -271.5m * (1 - 35.15%)) [loss with tax shield]
Current Ratio = 1.78 (Total Current Assets 2.45b / Total Current Liabilities 1.38b)
Debt / Equity = 0.71 (Debt 3.95b / totalStockholderEquity, last quarter 5.57b)
Debt / EBITDA = 25.82 (Net Debt 3.58b / EBITDA 138.7m)
Debt / FCF = 7.23 (Net Debt 3.58b / FCF TTM 495.0m)
Total Stockholder Equity = 5.88b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.44% (Net Income -530.2m / Total Assets 11.79b)
RoE = -9.02% (Net Income TTM -530.2m / Total Stockholder Equity 5.88b)
RoCE = -2.77% (EBIT -271.5m / Capital Employed (Equity 5.88b + L.T.Debt 3.92b))
RoIC = -1.78% (negative operating profit) (NOPAT -176.1m / Invested Capital 9.92b)
WACC = 6.51% (E(6.28b)/V(10.23b) * Re(10.19%) + D(3.95b)/V(10.23b) * Rd(1.01%) * (1-Tc(0.35)))
Discount Rate = 10.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF Debug] Terminal Value 82.78% ; FCFF base≈573.8m ; Y1≈526.3m ; Y5≈468.7m
Fair Price DCF = 12.00 (EV 11.77b - Net Debt 3.58b = Equity 8.19b / Shares 682.1m; r=6.51% [WACC]; 5y FCF grow -10.37% → 2.90% )
EPS Correlation: -88.24 | EPS CAGR: -13.56% | SUE: 0.24 | # QB: 0
Revenue Correlation: -90.03 | Revenue CAGR: -4.15% | SUE: 1.54 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.16 | Chg30d=-0.047 | Revisions Net=-14 | Analysts=17
EPS current Year (2026-12-31): EPS=0.79 | Chg30d=-0.123 | Revisions Net=-16 | Growth EPS=-12.1% | Growth Revenue=-0.8%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=-0.150 | Revisions Net=-8 | Growth EPS=+7.9% | Growth Revenue=+2.2%